Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Cancer|March 13, 2016
Patient preferences regarding incidental genomic findings discovered during tumor profilingMelinda L Yushak, Gang Han, Sara Bouberhan, et al.
British Journal of Clinical Pharmacology|November 9, 2024
Population pharmacokinetics and exposure-response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBYMita Kuchimanchi, Trine Lembrecht Jørgensen, Eva Hanze, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2026
Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0Jamie L Lesnock, Sarah Temin, Sara Bouberhan, et al.
Signal Transduction and Targeted Therapy|December 18, 2025
Hypoxia induced VEGF secretion promotes resistance to bispecific T-cell engagersMengyao Xu, Syem K Barakzai, Raj Kumar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 29, 2022
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial CancerPanagiotis A Konstantinopoulos, Elizabeth K Lee, Niya Xiong, et al.
JAMA Oncology|July 28, 2022
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial CancerPanagiotis A Konstantinopoulos, Allison A Gockley, Niya Xiong, et al.
JCO Precision Oncology|April 10, 2025
Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial CancerPanagiotis A Konstantinopoulos, Mingyang Cai, Elizabeth K Lee, et al.
Nature Communications|December 3, 2025
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trialPanagiotis A Konstantinopoulos, Ningxuan Zhou, Richard T Penson, et al.
Gynecologic Oncology|May 20, 2025
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancerElizabeth K Lee, Niya Xiong, Carolyn Krasner, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 5, 2025
Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxelDana M Chase, Jørn Herrstedt, Eirwen M Miller, et al.
Pageof 3